Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03179878 · ClinicalTrials.gov registry record · Phase 1

Safety and Tolerability of SYNB1020-CP-001

A Phase 1 study, sponsored by Synlogic.

Completed
Registry status
Phase 1
Development phase
52
Enrollment target

NCT03179878 is a Phase 1 study that has completed, run by Synlogic. The registered enrollment target is 52 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03179878, a Phase 1 study, has completed, sponsored by Synlogic.

COMPLETED
Registry status
Phase 1
Development phase
52 participants
Enrollment target

Study Summary

A Phase 1, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1020 in Healthy Adult Volunteers to Evaluate Safety, Tolerability, Dosing, and Pharmacodynamics

Interventions

  • DRUG Placebo
  • DRUG SYNB1020

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2017-06-16
Est. Completion 2018-04-11
Phase Phase 1

Sponsor

Synlogic

10 total trials

What the Registry Record Tells You About NCT03179878

The ClinicalTrials.gov registry entry for NCT03179878 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synlogic, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03179878 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03179878 about?

NCT03179878 is a clinical study titled "Safety and Tolerability of SYNB1020-CP-001". A Phase 1, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1020 in Healthy Adult Volunteers to Evaluate Safety, Tolerability, Dosing, and Pharmacodynamics

What is the current status of trial NCT03179878?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2017-06-16. Estimated completion is 2018-04-11.

What interventions are being tested in trial NCT03179878?

The interventions under investigation include: Placebo (DRUG), SYNB1020 (DRUG).

Who is sponsoring clinical trial NCT03179878?

This trial is sponsored by Synlogic, which has 10 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.